The COVID-19 vaccine may still be slowly rolling out, but the influenza vaccine has been and still is available — and many more Americans have reported getting it or planning to get it during this flu season, exceeding past numbers and catapulting the nation to a new milestone threshold. It’s always a good idea to get the flu vaccine, but … Continue reading
7
A preliminary study from Israel suggests people vaccinated against COVID-19 have lower viral loads, which are linked to less spread of the virus.
5
NPR said it reviewed documents by One Medical leadership advising practitioners that the company is "not policing" who gets vaccines.
8
You’re reading The Waugh Zone, our daily politics briefing. Sign up now to get it by email in the evening.The question of whether key workers should be fast-tracked for Covid vaccinations has been a simmering topic for several weeks. But after evidence to the Commons science and technology committee on Wednesday, will the whole issue now boil over?Priti Patel made plain last month that she wanted police, firefighters and other “front line workers” given greater priority (after Met Police chief Cressida Dick said she was “baffled” why her officers weren’t already). Keir Starmer made a big political play of demanding teachers should get the jab at half-term. The idea is popular too. An Opinium/Observer poll found almost 94% of the public think some workers should qualify for vaccine priority, either alongside or above some older age groups. More than half (54%) backed prioritisation for teachers, and a similar proportion (53%) backed the move for police.Yet thanks to some candour from the deputy chair of the Joint Committee on Vaccinations and Immunisation (JCVI), we now know the idea looks dead in the water. In another newsworthy session of the sci and tech committee, Professor Anthony Harnden let slip that JCVI had completed its advice for Phase 2 of the vaccine programme to follow jabs of all over-50s after mid-April.“We have decided it,” he said, clearly taking questioner Zara Sultana and chair Greg Clark by surprise. “It is with ministers at the moment.” And just as importantly, Harnden made plain what the Phase 2 advice would be: stick to priority by age and underlying health conditions, not occupation.A “very careful” look at the data, including the ONS school survey of infection, found that teachers weren’t at any greater risk than the general public, the prof said. In fact there were other jobs with a much higher risk, like noisy meat processing plants where people had to shout and little ventilation. He could have added that shopworkers are also at much higher risk than teachers as they work with adults not low-risk children (but low-paid shopworkers, unlike public sector staff, have few politicians lobbying for them). Still, given teachers are now facing the huge workload of setting exam grades this year, they may continue to think Gavin Williamson has not batted hard for them in Whitehall.Prof Harnden stressed that making age the key determinant for priority was simple, easily understood, deliverable and quick. But he also said “if you start picking out certain groups” according to occupation you slow down the entire programme and “some people will be exposed to the virus and actually suffer harm that there would not have been otherwise”.“Ultimately we need to stick with the science, and you politicians need to decide the other things,” is how Harnden summed up his advice. Given that the government has long said the JCVI advice is paramount, it’s difficult to see how Boris Johnson would risk giving any key worker priority now, not least as choosing one group would open up a can of worms. Jabs not jobs is what matters.Of course, the government’s hope is that the vaccination rollout will continue its rapid progress so much that few people will complain, even cops, teachers, firefighters and others. Everyone over 18 is officially due to be jabbed by the end of July and unofficially government insiders think they’ll be done much sooner.Just imagine if June 21 is not only the day all lockdown restrictions are removed, but also the date by which the entire adult population gets their first dose?Boris Johnson joked at PMQs that Keir Starmer’s inconstant approach to policy on Covid was like a “druidical rocking stone”. But you can bet that if unlockdown is matched by every-adult vaccination on the day of the summer solstice, the PM himself will be dancing like a stoner at Stonehenge.Related...Exam Grades Will Not Be Decided By Algorithm This Year, Gavin Williamson Confirms5 Things You Might Have Missed In The Small Print Of Boris Johnson's RoadmapBoris Johnson Told £700m Catch Up Plan 'Not Enough' To Help Children Who Missed School
5
Moderna shipped a new version of its coronavirus vaccine to the NIH so that it could be tested in people.
8
Covax is aimed at equitable access to covid-19 vaccines globally. It plans to roll out over 2 billion doses by the end of the year, with at least 1.3 billion going to lower-income countries at no cost to their governments
3
An advisory committee for the agency will further review the vaccine this Friday.
10
Pfizer and Moderna have improved manufacturing capabilities and plan to deliver doses to the US ahead of schedule.
3
CVS's vaccine rollout plan now includes six new states and will continue to expand as more supply becomes available, the company said.
2
Conspiracy theorists might be targeting people of color with vaccine misinformation, as Latino and Asian Americans were targeted before the election.
8
North Korea is well-practiced at drug smuggling and hacking, and needs as much foreign currency as it can get.
9
Johnson & Jonhson's coronavirus vaccine is the only one that's been tested out in the US as just one shot.
10
The one-dose vaccine was particularly effective at preventing severe illness, according to documents released Wednesday by US regulators.
8
Johnson & Johnson’s single-shot COVID-19 vaccine works against all known variants of the coronavirus, according to new data released today, with the FDA saying the one-dose drug meets its requirements for Emergency Authorization Approval (EUA) review. It’s a big step forward for what could be the third vaccine for COVID-19 to be deployed in the US, and one which has … Continue reading
2
Global Foot and Mouth Disease (FMD) Vaccine Market has been brewing up and influencing the international economy with respect to revenue, growth rate, sale, market share, and size.The Global Foot and Mouth Disease (FMD) Vaccine Market research report provides a rational explanation to the reader to understand fundamental attributes of the Foot and Mouth Disease (FMD) Vaccine industry, which includes lucrative business strategies, market demands, leading players of the market, and growth prospects.This is the only report that is inclusive of the current effect of the coronavirus on the market and its future trends.The coronavirus has widely impacted the world economy, and its aftereffects are elucidated in detail in the report for the Foot and Mouth Disease (FMD) Vaccine market.Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1608Key players in the FMD vaccine market include:AgrovetBiogénesis BagoEmpresa Colombiana de Productos Veterinarios S.A. Vecol S.AFGBI - Federal Centre for Animal Health, Indian Immunologicals LimitedMerialVeterinary Serum and Vaccine Research InstituteFMD Center and Limor de ColombiaThe forecast estimation states the global Foot and Mouth Disease (FMD) Vaccine market is expected to dominate the economic sphere of the world with significant growth in the coming years.The growth is boosted by a change in demand patterns, rapidly developing infrastructure, technological advancements, and product advancements.The current and emerging trends are expected to shape up the industry and help in gaining a strong foothold in the global market to contribute to the revenue generation.The Global Foot and Mouth Disease (FMD) Vaccine market is further analyzed on the basis of key companies operating in the business sphere and major geographical regions where the market has a substantial size and growth rate.Market has been divided by Product as:Conventional VaccinesEmergency VaccinesTo read more about the report @ https://www.reportsanddata.com/report-detail/foot-and-mouth-disease-fmd-vaccine-marketMarket has been divided by application as:CattleSheepGoatsPigsAntelopeDeersBisonGazellesCamelidsZonal Partition of the Market: North America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa.The report covers extensive analysis of market segments that are anticipated to lead by the end of the forecast period (2020-2027).The report puts a special emphasis on the upstream raw materials, downstream buyers, industrial chain analysis, technological and product advancements, and production and manufacturing capacities of the Foot and Mouth Disease (FMD) Vaccine market.
Prefilled Syringe Market 2021Prefilled Syringes are medical syringes filled with a single dosage of vaccine or therapeutic molecules to which a needle is already attached by the manufacturer.Conventionally, metal or glass syringes have been popularly used, but lately, there has been an increasing interest in plastic and disposable syringes to achieve higher sterilization and prevent reuse.This has stimulated the market in the medical sector for compact and safe prefilled syringes over traditional glass vials for parental drug packaging and delivery.The global prefilled syringe market was valued at USD 5,120 million in 2019 and is expected to grow at a 9.2% CAGR during the forecast study period 2020 – 2029.Get a  Sample copy of this report :https://straitsresearch.com/report/Prefilled Syringe-Market/request-sampleKey PlayersBecton, Dickinson and Company (US),Gerresheimer (Germany),SCHOTT AG (Germany),West Pharmaceutical Services, Inc. (US),Baxter International Inc. (US),Ompi (Italy),Continue...Recent DevelopmentsIn 2019, Hikma PharmaceuticalsPLC, a multinational pharmaceutical company, launched a new prefilled syringe capability, for Heparin Sodium Injections, in the US through its affiliate, Hikma Pharmaceuticals USA Inc.In January 2019, Schott AG, a pharmaceutical packaging company, launched a customizable prefilled syringe in India.Prefilled Syringe Market: SegmentationBy TypeDisposableReusableBy MaterialGlass-basedPlastic-basedBy DesignSingle-chamber Prefilled SyringesDual-chamber Prefilled SyringesCustomized Prefilled SyringesBy TherapeuticLarge MoleculesSmall MoleculesBy ApplicationAnaphylaxisRheumatoid ArthritisDiabetesOthers (Cancer, Multiple Sclerosis, and others)By End-userHospitalsMail Order PharmaciesAmbulatory Surgery CentersYears that have been considered for the study of this report are as follows:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year: 2021 to 2029Regional Segmentation:North America (The US, Canada, and Mexico)Europe (Germany, France, the UK, and Rest of the World)Asia Pacific (China, Japan, India, and Rest of Asia Pacific)Latin America (Brazil and Rest of Latin America.)Middle East & Africa (Saudi Arabia, the UAE, South Africa, and Rest of Middle East & Africa)Additionally, the analysis also delivers a comprehensive review of the crucial players on the Prefilled Syringe Market along with their company profiles, SWOT analysis, latest advancement and business plans.The analysis objectives of the report are:To equitably share in-depth info regarding the crucial elements impacting the increase of industry (growth capacity, chances, drivers and industry specific challenge and risks).To know the Prefilled Syringe Market by pinpointing its many sub segments.To profile the important players and analyze their growth plans.To endeavor the amount and value of the Prefilled Syringe Market sub-markets, depending on key regions (various vital states).To analyze the Global Prefilled Syringe Market concerning growth trends, prospects and also their participation in the entire sector.To examine and study the Global Prefilled Syringe Market size (volume and value) form the company, essential regions/countries, products and applications, background information and also predictions to 2029.Primary worldwide Global Prefilled Syringe Market manufacturing companies, to specify, clarify and analyze the product sales amount, value and market share, market rivalry landscape, SWOT analysis and development plans for the next coming years.To examine competitive progress such as expansions, arrangements, new product launches and acquisitions on the market.Explore Full Report with Detailed TOC, Charts, Tables and [email protected]://straitsresearch.com/report/Prefilled Syringe-MarketWould you like to discuss Prefilled Syringe Market challenges with the experts at Straits ResearchFor more details, please contact us -Email: [email protected]: 825 3rd Avenue, New York, NY, USA, 10022Tel: +1 6464807505, +44 203 318 2846Website:https://straitsresearch.com
Photo by Smith Collection/Gado/Getty Images Health care company One Medical gave COVID-19 vaccines to people who were ineligible under local guidelines, including friends and family of company leadership, NPR reported. Health departments in Washington state and California said they stopped distributing doses to One Medical after finding out that the company was not sticking to eligibility rules. The company was given vaccine doses in a few states, including Washington and California. Internal messages obtained by NPR show that doctors raised concerns about patients jumping the line for vaccinations ahead of people who where higher priority for the shots. Now, Alameda County, California and the Washington State Department of Health have refused to give the company more doses. In... Continue reading…
2
Market Statistic, LLP has recently published a research study about Global Tetanus Vaccine Market.The report illustrates the market thoroughly and has offer a structural evaluation analysis of the market.‘Global Tetanus Vaccine Market comprises of basic market dynamics like the driving and restraining factors, industry trends and growth opportunities in the forecast period (2021-2027).’ The report offers detailed analysis & statistics of the different market segments globally.Get sample pages from this research report @ https://www.marketstatistic.com/request-sample/817 The leading market players covered in this report are: Changchun Changsheng Life Sciences Wuhan Institute of Biological Products Chengdu Institute of Biological Products Sanofi-Pasteur Shanghai Institute of Biological Products Beijing Tiantan Biological Products GSK The scope of all these distinct segments has been covered in the report and has been researched separately.This is likely to help investors decide where to invest in the right industry segment.Additionally, the research report also offers complete analysis of industry players¬- this comprises extensive company product as well as company profile specifications.
An extra 150,000 people in England with severe learning disabilities are to be prioritised for a Covid vaccine, the government has announced.Professor Anthony Harnden, deputy chair of the Joint Committee on Vaccinations and Immunisation, told MPs that GPs would now write to everyone on their learning disability register to invite them for a jab.Using the register also means some people classed as having a moderate learning disability will get the jab, but not those with a mild disability as campaigners had hoped.There is no change to the classification of priority groups, but the move is an operational shift to capture more people with profound disability rather than rely on individual classifications of their condition.Harnden said the decision was driven by the need to target those most at risk more quickly.“What I don’t want to happen is lots of families who are rightly concerned about their relatives with mild learning disabilities to start banging at the door of their GPs,” he told the Commons Science and Technology Committee.Families of those with learning disabilities have demanded change and DJ Jo Whiley had pleaded for people such as her sister, Frances, to be vaccinated as quickly as possible.Whiley spoke out when she was offered the jab before her sister, who has a rare genetic syndrome and lives in residential care. The broadcaster’s sister is recovering after being admitted to hospital with coronavirus earlier this week.But NHS England will not be following the decision of the Scottish government to include everyone with a learning disability, including mild disability, for the jab. Lib Dem leader had this week demanded such a policy for the whole of the UK.In England, that would have meant an extra 1.5m people getting moved up the priority list, and Professor Harnden stressed that there was no clinical reason for that given that people with mild disability were at no greater risk of Covid than the general population.“We don’t want everybody who has a relative with a mild learning disability to come forward to be vaccinated now because that would cause problems because there’s over one and a half million of those individuals. And it is really important that we try to find who has got severe, profound learning disabilities.“I and the JCVI are very personally very concerned about this issue because people with learning disabilities are a hugely disadvantaged sector of our society. And I would like to implore any GPs which are immunising within group six now to reach out to those that they know have learning disabilities and prioritise them within group six.”He added: “All those on the learning disability register as registered by their GP should be eligible for immunisation now. [...]“This will include about another 150,000 or so individuals with learning disabilities. However, there’s no evidence at all that the individual risk of someone with very mild learning disabilities is any different from someone else of their age.”All those with learning disabilities living in shared residential care should already be getting priority for the jab.People with a “severe or profound” learning disability in England and Wales were already in priority group six for the coronavirus vaccine, along with all those with learning disability living in residential care homes.And adults with Down’s Syndrome have already been offered a jab, in priority group 4, as part of the UK’s target to vaccinate 15m people by mid-February.A report from Public Health England in November found that people with severe learning disability were up to six times more likely to die from Covid-19 and, in the 18-to-34 age group, their risk was 30 times higher.Care minister Helen Whately said: “I have heard first-hand how tough this pandemic has been for people with learning disabilities and their families. We are determined those more at risk from Covid should be vaccinated as soon as possible.“Following the JCVI’s updated advice and to make this process simpler and faster, we will be inviting everyone for vaccination who is on their GP’s learning disability register. This will mean those who are at a higher risk from the virus can get the protection they need.”Related...PM Urged To Give Vaccine Priority To People With Learning Disabilities1.7m More People In England Will Be Told To ShieldKatie Price's Son Harvey Announces New Role With Learning Disability Charity Mencap
10
Vaccine is no child’s play!In the fight against the coronavirus pandemic, those aged under 21 have received limited focus.This is primarily because the virus affects older people much more.Oxford and AstraZeneca, Johnson & Johnson, Novovax, and Covaxin have announced plans and clinical trials for vaccines catering to children aged 12 and above.Pfizer and Moderna have already begun their trials.To build herd immunity in the community and bring this population back to school, vaccination becomes necessary.For a pandemic to end about 70-90% of the population will need to be vaccinated.Governments are likely to face challenges including those who do not want to get vaccinated.India has a largely young population so the fight against the virus will depend heavily upon how quickly they are vaccinated.Besides, the longer the pandemic rages on, the worse the effects on education which is currently online.Here's the lowdown about COVID-19 vaccines for children:https://transfin.in/when-will-covid-19-vaccines-be-available-for-children-and-teenagers
More

Top